What's Happening?
858 Therapeutics, a biotechnology company based in San Diego, has announced preliminary results from its first-in-human Phase 1/2 trial of the PARG inhibitor ETX-19477. The trial, which focuses on patients with advanced solid tumors, has shown promising
efficacy, particularly in BRCA-mutated platinum-resistant ovarian cancer and HR+/HER2- breast cancer. The data, which will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, indicates a 57% objective response rate in a subset of patients. The trial has also demonstrated a favorable safety profile, with low rates of hematologic toxicity, supporting further development of ETX-19477 as a monotherapy and in combination strategies.
Why It's Important?
The results from this trial are significant as they provide the first clinical proof-of-concept for PARG inhibition in treating ovarian and breast cancer. This development could potentially expand treatment options for patients with these types of cancer, particularly those with BRCA mutations. The promising efficacy and safety profile of ETX-19477 could lead to new therapeutic strategies, offering hope for improved outcomes in cancer treatment. The success of this trial could also stimulate further research and investment in PARG inhibitors, potentially leading to breakthroughs in cancer therapy.
What's Next?
858 Therapeutics is continuing to enroll patients in Phase 2 monotherapy expansion cohorts, focusing on BRCA-mutated ovarian and breast cancer. The company plans to explore combination approaches that could expand the treatable patient population. The upcoming presentation at the ASCO Annual Meeting will provide more detailed data and insights into the trial's outcomes, potentially attracting interest from the broader oncology community and stakeholders in the pharmaceutical industry.
